Captisol, a Ligand technology
Ligand-owned, Captisol® was invented in 1990 by scientists at the University of Kansas Higuchi Biosciences Center for use in drug development and formulation.
The Captisol® technology is used to address the limitations of currently marketed drugs. FDA-approved, Captisol-enabled® medications are marketed by: Pfizer, Bristol-Myers Squibb and Baxter International. Captisol® also has License and Supply Agreements (LSAs) in place with a number of pharmaceutical companies worldwide with Captisol-enabled® product candidates. Routes of administration investigated include parenteral, oral, ophthalmic, nasal, topical, oral, and inhalation.
Captisol® is a patent protected, uniquely modified cyclodextrin, whose chemical structure was rationally designed to enable the creation of new products by significantly improving solubility, stability, bioavailability and dosing of active pharmaceutical ingredients (APIs).
|Sales markets||UK; Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America|
|Primary business activity||Service|
|Affiliated categories:||Excipients More|
CPhI North America 201930 April - 2 May 2019 Chicago, USA We were at stand 2452 See our Exhibitor Profile See full Exhibitor List
Our Top products
Categories affiliated with Captisol, a Ligand technology
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation